Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US court rules for Novo Nordisk in Prandin patent listing dispute

This article was originally published in Scrip

Executive Summary

A recent US federal appeals court ruling means that Caraco Pharmaceutical, a subsidiary of Sun Pharmaceutical Industries, could face an uphill battle in its effort to introduce a generic version of Novo Nordisk's antidiabetic Prandin (repaglinide) and prove that it does not overlap and infringe the protected use.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel